Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thrombin alfa - ZymoGenetics

Drug Profile

Thrombin alfa - ZymoGenetics

Alternative Names: Recombinant thrombin - ZymoGenetics; Recothrom; rhThrombin

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZymoGenetics
  • Developer Bayer HealthCare; ZymoGenetics
  • Class Antihaemorrhagics; Blood coagulation factors; Serine endopeptidases
  • Mechanism of Action Fibrin stimulants; Serine endopeptidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Surgical blood loss

Most Recent Events

  • 19 Mar 2018 Baxter International completes the acquisition of thrombin alfa (RECOTHROM) from Mallinckrodt
  • 08 Jan 2018 Baxter International entered into an agreement to acquire thrombin alfa from Mallinckrodt for Surgical blood loss
  • 01 Feb 2016 Mallinckrodt plc acquired the haemostasis portfolio of The Medicines Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top